The bioinformatics and experimental analysis of AlkB family for prognosis and immune cell infiltration in hepatocellular carcinoma.
AlkB family
Hepatocellular carcinoma
Immune cell infiltration
Molecular profiles
Prognosis
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
07
2021
accepted:
16
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Serving as N6-methyladenosine demethylases, the AlkB family is involved in the tumorigenesis of hepatocellular carcinoma (HCC). However, the molecular profiles and clinical values of the AlkB family in HCC are not well known. Several bioinformatics tools and In this study expression levels of ALKBH1/2/3/4/7 were all remarkably increased in HCC tissues when compared with normal tissues. Quantitative PCR (qPCR) and immunohistochemistry were used to validate the expression of AlkB family members in HCC tissues and normal liver tissues. In addition, high expression levels of ALKBH4 were negatively correlated with overall survival (OS) and disease-free survival (DFS) in patients with HCC. Increased ALKBH4 was also associated with pathological stage in HCC patients. The molecular profiles of AlkB family in HCC were mainly associated with peptidyl-serine modification, peptidyl-tyrosine modification, regulation of metal ion transport, etc. Furthermore, tumor-infiltrating immune cell analysis indicated that ALKBH1/2/3/4/5/6/7/8 and FTO were related to the infiltration of different immune cell, such as CD8+ T cells, macrophages, neutrophils, dendritic cells and CD4+ T cells. We also discovered that the methylation levels of ALKBH1/2/4/5/6/8 and FTO were remarkably reduced in HCC tissues. Collectively, our findings may deepen the understanding of specific molecular profiles of the AlkB family in HCC pathology. In particular, ALKBH4 could serve as a promising prognostic candidate for treating HCC, and these results might potentiate the development of more reliable therapeutic strategies for patients with HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Serving as N6-methyladenosine demethylases, the AlkB family is involved in the tumorigenesis of hepatocellular carcinoma (HCC). However, the molecular profiles and clinical values of the AlkB family in HCC are not well known.
METHODS
METHODS
Several bioinformatics tools and
RESULTS
RESULTS
In this study expression levels of ALKBH1/2/3/4/7 were all remarkably increased in HCC tissues when compared with normal tissues. Quantitative PCR (qPCR) and immunohistochemistry were used to validate the expression of AlkB family members in HCC tissues and normal liver tissues. In addition, high expression levels of ALKBH4 were negatively correlated with overall survival (OS) and disease-free survival (DFS) in patients with HCC. Increased ALKBH4 was also associated with pathological stage in HCC patients. The molecular profiles of AlkB family in HCC were mainly associated with peptidyl-serine modification, peptidyl-tyrosine modification, regulation of metal ion transport, etc. Furthermore, tumor-infiltrating immune cell analysis indicated that ALKBH1/2/3/4/5/6/7/8 and FTO were related to the infiltration of different immune cell, such as CD8+ T cells, macrophages, neutrophils, dendritic cells and CD4+ T cells. We also discovered that the methylation levels of ALKBH1/2/4/5/6/8 and FTO were remarkably reduced in HCC tissues.
CONCLUSIONS
CONCLUSIONS
Collectively, our findings may deepen the understanding of specific molecular profiles of the AlkB family in HCC pathology. In particular, ALKBH4 could serve as a promising prognostic candidate for treating HCC, and these results might potentiate the development of more reliable therapeutic strategies for patients with HCC.
Identifiants
pubmed: 34557360
doi: 10.7717/peerj.12123
pii: 12123
pmc: PMC8418211
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12123Informations de copyright
©2021 Peng et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
PLoS One. 2020 Nov 19;15(11):e0242058
pubmed: 33211709
Nat Commun. 2019 Jun 25;10(1):2782
pubmed: 31239444
Aging (Albany NY). 2021 Mar 19;13(7):9679-9692
pubmed: 33744868
Mol Cancer. 2020 Nov 12;19(1):160
pubmed: 33183286
Geroscience. 2020 Oct;42(5):1307-1321
pubmed: 32451847
Ann Transl Med. 2020 Dec;8(24):1674
pubmed: 33490186
World J Gastroenterol. 2019 Jul 28;25(28):3704-3721
pubmed: 31391767
Ann Transl Med. 2020 Apr;8(8):553
pubmed: 32411776
Front Genet. 2020 Aug 25;11:994
pubmed: 33193582
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Ann Transl Med. 2020 Mar;8(6):373
pubmed: 32355817
Nucleic Acids Res. 2017 Jan 4;45(D1):D888-D895
pubmed: 27899673
DNA Repair (Amst). 2020 Mar;87:102804
pubmed: 31981739
Front Cell Dev Biol. 2021 Jun 03;9:633927
pubmed: 34150745
J Cancer Res Clin Oncol. 2020 Jul;146(7):1711-1723
pubmed: 32356177
Antioxid Redox Signal. 2018 Apr 20;28(12):1120-1136
pubmed: 28938844
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Oncol Lett. 2019 Aug;18(2):1179-1188
pubmed: 31423178
Geroscience. 2020 Apr;42(2):687-701
pubmed: 31981007
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Geroscience. 2020 Apr;42(2):785-800
pubmed: 32221778
Cell Mol Life Sci. 2021 Jan;78(1):129-141
pubmed: 32642789
J Exp Clin Cancer Res. 2020 Nov 23;39(1):257
pubmed: 33228738
Clin Transl Med. 2021 Mar;11(3):e352
pubmed: 33783988
BMC Cancer. 2021 Jun 10;21(1):686
pubmed: 34112124
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Protein Sci. 2018 Jan;27(1):233-244
pubmed: 28940711
EMBO J. 2020 Oct 15;39(20):e104514
pubmed: 32964498
Mol Cell. 2020 Jun 18;78(6):1192-1206.e10
pubmed: 32470318
Oxid Med Cell Longev. 2020 Oct 9;2020:3580719
pubmed: 33101586
J Biol Chem. 2020 May 22;295(21):7317-7326
pubmed: 32284330
Mol Cancer. 2020 Aug 10;19(1):123
pubmed: 32772918
Sci Rep. 2019 Sep 13;9(1):13249
pubmed: 31519943
Ann Transl Med. 2020 Sep;8(18):1192
pubmed: 33241041
Biochem Pharmacol. 2020 Dec;182:114258
pubmed: 33017575
Ann Transl Med. 2020 Dec;8(24):1667
pubmed: 33490179
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25284-25292
pubmed: 32989163
Geroscience. 2020 Jun;42(3):819-832
pubmed: 32221779
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Ann Transl Med. 2020 Dec;8(24):1653
pubmed: 33490165
Ann Transl Med. 2020 Mar;8(6):387
pubmed: 32355831
ACS Chem Biol. 2019 Jul 19;14(7):1418-1425
pubmed: 31188562
Biotechnol Adv. 2020 Dec;45:107656
pubmed: 33181242
Am J Transl Res. 2019 Sep 15;11(9):6084-6092
pubmed: 31632576
Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20159-20170
pubmed: 32747553